Weill Cornell Medicine Research Highlighted by Prostate Cancer Foundation’s “Top 5 Prostate Cancer Research Stories of 2017”
In January 2018, the Prostate Cancer Foundation recognized the developments of PSMA radionuclide therapy as one of the top 5 research stories of 2017, highlighting the recent work from Weill Cornell Medicine’s Department of Urology as a driving force behind this effort.
Prostate Cancer Foundation Announces 2017 PCF Challenge Awards to Accelerate the Development of New Treatments for Advanced Prostate Cancer
WASHINGTON, D.C., October 5, 2017 – The Prostate Cancer Foundation (PCF) today announced awards totaling $7.515 million to fund new 2017 PCF Challenge Awards supporting international, cross-disciplinary teams of investigators conducting pioneering research into critical, unmet medical needs in areas that have the highest potential for impacting and extending lives of men with advanced prostate cancer. This year’s awards include innovative research projects – such as testing several novel radiation-emitting prostate cancer-targeting treatments in advanced pr
First Clinical Trial of New Targeted Molecular Therapy in U.S. Takes Aim at Incurable Prostate Cancer
NewYork-Presbyterian and Weill Cornell Medicine clinicians in progress on Phase 1 clinical trial of PSMA-Targeted Therapeutic Agent for the Treatment for Metastatic Prostate Cancer
NewYork-Presbyterian and Weill Cornell Medicine have begun the first clinical trial in the U.S. that uses a small molecule, 177Lu-PSMA-617, to treat men with progressive prostate cancer that has spread beyond the prostate, or is metastatic, and is no longer responding to hormonal therapy.
Dr. Neil H. Bander completed fellowship training in urological oncology under Dr. Willet F. Whitmore, Jr. and an NIH Immunology Training Fellowship in the laboratory of Dr. Lloyd Old, both at Memorial Sloan-Kettering Cancer Center in New York City. After coming to NewYork-Presbyterian Hospital-Weill Cornell Medicine (NYPH/WCM), he focused on clinical urological oncology and the development of monoclonal antibodies for targeted cancer therapy.